451 related articles for article (PubMed ID: 33497016)
1. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
Di Maio VC; Barbaliscia S; Teti E; Fiorentino G; Milana M; Paolucci S; Pollicino T; Morsica G; Starace M; Bruzzone B; Gennari W; Micheli V; Yu La Rosa K; Foroghi L; Calvaruso V; Lenci I; Polilli E; Babudieri S; Aghemo A; Raimondo G; Sarmati L; Coppola N; Pasquazzi C; Baldanti F; Parruti G; Perno CF; Angelico M; Craxì A; Andreoni M; Ceccherini-Silberstein F;
Liver Int; 2021 Aug; 41(8):1802-1814. PubMed ID: 33497016
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
Rossetti B; Paglicci L; Di Maio VC; Cassol C; Barbaliscia S; Paolucci S; Bruzzone B; Coppola N; Montagnani F; Micheli V; Monno L; Zanelli G; Santantonio T; Cuomo N; Caudai C; Zazzi M; Ceccherini-Silberstein F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet C
Infez Med; 2021 Jun; 29(2):242-251. PubMed ID: 34061790
[TBL] [Abstract][Full Text] [Related]
3. Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life.
Ren S; Wei F; Jin Y; Lu J; He Z; Ma L; Zheng Y; Wang J; Chen X
Antivir Ther; 2020; 25(5):245-255. PubMed ID: 32936785
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
5. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
Di Maio VC; Cento V; Lenci I; Aragri M; Rossi P; Barbaliscia S; Melis M; Verucchi G; Magni CF; Teti E; Bertoli A; Antonucci F; Bellocchi MC; Micheli V; Masetti C; Landonio S; Francioso S; Santopaolo F; Pellicelli AM; Calvaruso V; Gianserra L; Siciliano M; Romagnoli D; Cozzolongo R; Grieco A; Vecchiet J; Morisco F; Merli M; Brancaccio G; Di Biagio A; Loggi E; Mastroianni CM; Pace Palitti V; Tarquini P; Puoti M; Taliani G; Sarmati L; Picciotto A; Vullo V; Caporaso N; Paoloni M; Pasquazzi C; Rizzardini G; Parruti G; Craxì A; Babudieri S; Andreoni M; Angelico M; Perno CF; Ceccherini-Silberstein F;
Liver Int; 2017 Apr; 37(4):514-528. PubMed ID: 28105744
[TBL] [Abstract][Full Text] [Related]
6. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H
J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932
[TBL] [Abstract][Full Text] [Related]
7. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
[TBL] [Abstract][Full Text] [Related]
9. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.
von Felden J; Vermehren J; Ingiliz P; Mauss S; Lutz T; Simon KG; Busch HW; Baumgarten A; Schewe K; Hueppe D; Boesecke C; Rockstroh JK; Daeumer M; Luebke N; Timm J; Schulze Zur Wiesch J; Sarrazin C; Christensen S
Aliment Pharmacol Ther; 2018 May; 47(9):1288-1295. PubMed ID: 29536554
[TBL] [Abstract][Full Text] [Related]
10. Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C.
Itakura J; Kurosaki M; Kakizaki S; Amano K; Nakayama N; Inoue J; Endo T; Marusawa H; Hasebe C; Joko K; Wada S; Akahane T; Koushima Y; Ogawa C; Kanto T; Mizokami M; Izumi N
JHEP Rep; 2020 Oct; 2(5):100138. PubMed ID: 32817930
[TBL] [Abstract][Full Text] [Related]
11. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
12. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
Dietz J; Di Maio VC; de Salazar A; Merino D; Vermehren J; Paolucci S; Kremer AE; Lara M; Pardo MR; Zoller H; Degasperi E; Peiffer KH; Sighinolfi L; Téllez F; Graf C; Ghisetti V; Schreiber J; Fernández-Fuertes E; Boglione L; Muñoz-Medina L; Stauber R; Gennari W; Figueruela B; Santos J; Lampertico P; Zeuzem S; Ceccherini-Silberstein F; García F; Sarrazin C; ; ;
J Hepatol; 2021 Apr; 74(4):801-810. PubMed ID: 33220331
[TBL] [Abstract][Full Text] [Related]
13. Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
McPhee F; Hernandez D; Zhou N
Antivir Ther; 2017; 22(3):237-246. PubMed ID: 28008868
[TBL] [Abstract][Full Text] [Related]
14. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.
Howe AYM; Rodrigo C; Cunningham EB; Douglas MW; Dietz J; Grebely J; Popping S; Sfalcin JA; Parczewski M; Sarrazin C; de Salazar A; Fuentes A; Sayan M; Quer J; Kjellin M; Kileng H; Mor O; Lennerstrand J; Fourati S; Di Maio VC; Chulanov V; Pawlotsky JM; Harrigan PR; Ceccherini-Silberstein F; Garcia F;
JHEP Rep; 2022 May; 4(5):100462. PubMed ID: 35434589
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.
Kim KA; Lee S; Park HJ; Jang ES; Lee YJ; Cho SB; Kim YS; Kim IH; Lee BS; Chung WJ; Ahn SH; Kim S; Jeong SH
Clin Mol Hepatol; 2023 Apr; 29(2):496-509. PubMed ID: 36880209
[TBL] [Abstract][Full Text] [Related]
17. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J; Müllhaupt B; Buggisch P; Graf C; Peiffer KH; Matschenz K; Schattenberg JM; Antoni C; Mauss S; Niederau C; Discher T; Trauth J; Dultz G; Schulze Zur Wiesch J; Piecha F; Klinker H; Müller T; Berg T; Neumann-Haefelin C; Berg CP; Zeuzem S; Sarrazin C; ; ; ;
J Hepatol; 2023 Jan; 78(1):57-66. PubMed ID: 36031158
[TBL] [Abstract][Full Text] [Related]
18. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
20. Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway.
Kjellin M; Kileng H; Akaberi D; Palanisamy N; Duberg AS; Danielsson A; Kristiansen MG; Nöjd J; Aleman S; Gutteberg T; Goll R; Lannergård A; Lennerstrand J
Scand J Gastroenterol; 2019 Aug; 54(8):1042-1050. PubMed ID: 31424972
[No Abstract] [Full Text] [Related]
[Next] [New Search]
